1.68
+0.13(+8.39%)
Currency In USD
| Previous Close | 1.55 |
| Open | 1.55 |
| Day High | 1.7 |
| Day Low | 1.55 |
| 52-Week High | 9.97 |
| 52-Week Low | 1.15 |
| Volume | 3.08M |
| Average Volume | 3.45M |
| Market Cap | 260.6M |
| PE | -1.33 |
| EPS | -1.26 |
| Moving Average 50 Days | 2.77 |
| Moving Average 200 Days | 4.89 |
| Change | 0.13 |
If you invested $1000 in Humacyte, Inc. (HUMA) since IPO date, it would be worth $173.73 as of April 19, 2025 at a share price of $1.68. Whereas If you bought $1000 worth of Humacyte, Inc. (HUMA) shares 3 years ago, it would be worth $227.03 as of April 19, 2025 at a share price of $1.68.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Humacyte to Present Fourth Quarter and Full Year Financial Results and Provide Corporate Update on March 28, 2025
GlobeNewswire Inc.
Mar 26, 2025 12:00 PM GMT
DURHAM, N.C., March 26, 2025 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable, bioengineered human tissue at commercial scale, will release its financial results f
Humacyte, Inc. Announces Pricing of Public Offering of Common Stock
GlobeNewswire Inc.
Mar 26, 2025 12:35 AM GMT
DURHAM, N.C., March 25, 2025 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at commercial scale, today announced the pricing of an
Humacyte, Inc. Announces Proposed Public Offering of Common Stock
GlobeNewswire Inc.
Mar 25, 2025 8:01 PM GMT
DURHAM, N.C., March 25, 2025 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at commercial scale, today announced that it has comme
Data not available